GlassScriptPhysician profile
Neena Agarwala
NPI 1467419291
$16,833.81
in general payments reported to CMS, 2019-2025
32 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $700 · 2021: $1,430 · 2022: $7,032 · 2023: $4,551 · 2024: $845 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,120 · Consulting Fee: $1,695 · Food and Beverage: $1,689 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,120.00 |
| Consulting Fee | $1,694.99 |
| Food and Beverage | $1,688.70 |
| Education | $294.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $4,556.72 | 2022 | |
| Abbvie INC. | $3,462.64 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Sumitomo Pharma America, INC. | $2,468.40 | 2023-2025 | Myfembree |
| Becton, Dickinson and Company | $1,586.66 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $748.35 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $558.33 | 2023 | |
| Astellas Pharma US INC | $526.78 | 2020-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $467.22 | 2020-2023 | Phexxi |
| Therapeuticsmd, INC. | $381.33 | 2019-2022 | |
| Myovant Sciences INC. | $341.23 | 2021-2022 | |
| Agile Therapeutics, INC. | $248.39 | 2021-2023 | Twirla |
| Scynexis, INC. | $166.35 | 2022 | |
| Avion Pharmaceuticals | $140.47 | 2021-2022 | |
| Exact Sciences Corporation | $135.34 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $125.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124.76 | 2021 | |
| Roche Diagnostics Corporation | $117.40 | 2019 | |
| Viiv Healthcare Company | $100.23 | 2024 | |
| Lupin INC. | $75.09 | 2020 | |
| Hologic Sales and Service, LLC | $74.45 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $61.68 | 2020-2021 | |
| Dysis Medical, INC. | $56.02 | 2022 | |
| Caldera Medical, INC | $52.42 | 2022 | |
| Pfizer INC. | $50.00 | 2024 | |
| Endo Pharmaceuticals INC. | $43.88 | 2019-2020 | |
| Coopersurgical, INC. | $34.15 | 2021 | |
| Millicent US INC | $27.35 | 2024-2025 | Intrarosa |
| Amgen INC. | $24.38 | 2020 | |
| Shire North American Group INC | $22.56 | 2019 | |
| Adlon Therapeutics L.P. | $21.61 | 2020 | |
| Daiichi Sankyo INC. | $20.00 | 2022 | |
| Organon LLC | $14.62 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neena Agarwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.